Annual EBIT
-$759.59 M
-$186.41 M-32.52%
31 December 2022
Summary:
Mirati Therapeutics annual earnings before interest & taxes is currently -$759.59 million, with the most recent change of -$186.41 million (-32.52%) on 31 December 2022. During the last 3 years, it has fallen by -$186.41 million (-32.52%).MRTX EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
-$172.05 M
+$15.22 M+8.13%
30 September 2023
Summary:
Mirati Therapeutics quarterly earnings before interest & taxes is currently -$172.05 million, with the most recent change of +$15.22 million (+8.13%) on 30 September 2023.MRTX Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
-$764.87 M
+$14.39 M+1.85%
30 September 2023
Summary:
Mirati Therapeutics TTM earnings before interest & taxes is currently -$764.87 million, with the most recent change of +$14.39 million (+1.85%) on 30 September 2023.MRTX TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MRTX EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | -32.5% | +12.7% | -33.4% |
| 5 y5 years | -242.0% | -130.5% | -244.4% |
MRTX EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | >+9999.0% | -1952.1% | >+9999.0% |
Mirati Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2023 | - | -$172.05 M(-8.1%) | -$764.87 M(-1.8%) |
| June 2023 | - | -$187.27 M(-3.4%) | -$779.26 M(+1.3%) |
| Mar 2023 | - | -$193.82 M(-8.5%) | -$769.19 M(+1.3%) |
| Dec 2022 | -$759.59 M(+32.5%) | -$211.72 M(+13.6%) | -$759.59 M(+2.0%) |
| Sept 2022 | - | -$186.44 M(+5.2%) | -$744.94 M(+16.8%) |
| June 2022 | - | -$177.21 M(-3.8%) | -$638.00 M(+2.1%) |
| Mar 2022 | - | -$184.22 M(-6.5%) | -$624.98 M(+9.0%) |
| Dec 2021 | -$573.18 M(+55.2%) | -$197.07 M(+147.9%) | -$573.18 M(+18.8%) |
| Sept 2021 | - | -$79.50 M(-51.6%) | -$482.44 M(-1.9%) |
| June 2021 | - | -$164.19 M(+24.0%) | -$491.62 M(+19.2%) |
| Mar 2021 | - | -$132.42 M(+24.5%) | -$412.30 M(+11.6%) |
| Dec 2020 | -$369.36 M(+66.3%) | -$106.33 M(+19.9%) | -$369.36 M(+9.4%) |
| Sept 2020 | - | -$88.68 M(+4.5%) | -$337.68 M(+10.3%) |
| June 2020 | - | -$84.86 M(-5.2%) | -$306.06 M(+13.8%) |
| Mar 2020 | - | -$89.49 M(+19.9%) | -$268.83 M(+21.0%) |
| Dec 2019 | -$222.10 M(+116.4%) | -$74.65 M(+30.8%) | -$222.11 M(+25.4%) |
| Sept 2019 | - | -$57.06 M(+19.8%) | -$177.13 M(+18.9%) |
| June 2019 | - | -$47.64 M(+11.4%) | -$149.01 M(+14.6%) |
| Mar 2019 | - | -$42.76 M(+44.1%) | -$130.04 M(+26.7%) |
| Dec 2018 | -$102.63 M(+43.5%) | -$29.67 M(+2.5%) | -$102.63 M(+12.6%) |
| Sept 2018 | - | -$28.94 M(+0.9%) | -$91.18 M(+15.6%) |
| June 2018 | - | -$28.67 M(+86.8%) | -$78.84 M(+14.6%) |
| Mar 2018 | - | -$15.35 M(-15.8%) | -$68.79 M(-3.8%) |
| Dec 2017 | -$71.53 M(-14.6%) | -$18.23 M(+9.8%) | -$71.53 M(-2.2%) |
| Sept 2017 | - | -$16.60 M(-10.8%) | -$73.16 M(-3.9%) |
| June 2017 | - | -$18.62 M(+2.9%) | -$76.14 M(-4.5%) |
| Mar 2017 | - | -$18.09 M(-8.9%) | -$79.75 M(-4.8%) |
| Dec 2016 | -$83.78 M(+29.5%) | -$19.85 M(+1.4%) | -$83.78 M(+1.7%) |
| Sept 2016 | - | -$19.58 M(-11.9%) | -$82.41 M(+1.1%) |
| June 2016 | - | -$22.23 M(+0.5%) | -$81.56 M(+9.0%) |
| Mar 2016 | - | -$22.12 M(+19.6%) | -$74.85 M(+15.7%) |
| Dec 2015 | -$64.71 M(+66.9%) | -$18.49 M(-1.3%) | -$64.71 M(+14.2%) |
| Sept 2015 | - | -$18.72 M(+20.7%) | -$56.67 M(+16.9%) |
| June 2015 | - | -$15.52 M(+29.5%) | -$48.49 M(+12.5%) |
| Mar 2015 | - | -$11.99 M(+14.8%) | -$43.11 M(+11.2%) |
| Dec 2014 | -$38.77 M | -$10.44 M(-1.0%) | -$38.77 M(+10.2%) |
| Sept 2014 | - | -$10.55 M(+4.1%) | -$35.19 M(+4.0%) |
| June 2014 | - | -$10.13 M(+32.6%) | -$33.85 M(+10.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2014 | - | -$7.64 M(+11.4%) | -$30.61 M(-1.1%) |
| Dec 2013 | -$30.97 M(+51.1%) | -$6.86 M(-25.5%) | -$30.96 M(+1.6%) |
| Sept 2013 | - | -$9.21 M(+33.6%) | -$30.47 M(+11.9%) |
| June 2013 | - | -$6.89 M(-13.8%) | -$27.23 M(+8.6%) |
| Mar 2013 | - | -$8.00 M(+25.5%) | -$25.07 M(+22.3%) |
| Dec 2012 | -$20.50 M(+115.8%) | -$6.37 M(+6.8%) | -$20.50 M(+17.1%) |
| Sept 2012 | - | -$5.97 M(+26.0%) | -$17.50 M(+19.7%) |
| June 2012 | - | -$4.73 M(+38.3%) | -$14.62 M(+26.9%) |
| Mar 2012 | - | -$3.42 M(+1.4%) | -$11.52 M(+18.7%) |
| Dec 2011 | -$9.50 M(-35.3%) | -$3.38 M(+9.4%) | -$9.71 M(+11.1%) |
| Sept 2011 | - | -$3.09 M(+88.8%) | -$8.74 M(-14.8%) |
| June 2011 | - | -$1.63 M(+1.4%) | -$10.26 M(-13.9%) |
| Mar 2011 | - | -$1.61 M(-33.1%) | -$11.91 M(-18.7%) |
| Dec 2010 | -$14.68 M(-34.4%) | -$2.41 M(-47.7%) | -$14.66 M(-16.3%) |
| Sept 2010 | - | -$4.60 M(+40.1%) | -$17.52 M(-2.3%) |
| June 2010 | - | -$3.29 M(-24.6%) | -$17.93 M(-13.0%) |
| Mar 2010 | - | -$4.36 M(-17.3%) | -$20.61 M(-1.9%) |
| Dec 2009 | -$22.38 M(+201.2%) | -$5.27 M(+5.1%) | -$21.00 M(+226.0%) |
| Sept 2009 | - | -$5.01 M(-15.9%) | -$6.44 M(+22.4%) |
| June 2009 | - | -$5.96 M(+25.4%) | -$5.26 M(-22.8%) |
| Mar 2009 | - | -$4.76 M(-151.2%) | -$6.82 M(-13.4%) |
| Dec 2008 | -$7.43 M(-66.5%) | $9.29 M(-342.3%) | -$7.88 M(-65.8%) |
| Sept 2008 | - | -$3.83 M(-49.0%) | -$23.05 M(-9.0%) |
| June 2008 | - | -$7.52 M(+29.4%) | -$25.33 M(+7.5%) |
| Mar 2008 | - | -$5.81 M(-1.1%) | -$23.56 M(+11.0%) |
| Dec 2007 | -$22.20 M(+588.0%) | -$5.88 M(-4.0%) | -$21.23 M(+61.5%) |
| Sept 2007 | - | -$6.12 M(+6.5%) | -$13.14 M(+169.8%) |
| June 2007 | - | -$5.75 M(+65.1%) | -$4.87 M(+95.9%) |
| Mar 2007 | - | -$3.48 M(-257.9%) | -$2.49 M(-18.6%) |
| Dec 2006 | -$3.23 M(-75.9%) | $2.21 M(+2.5%) | -$3.06 M(-68.3%) |
| Sept 2006 | - | $2.15 M(-164.0%) | -$9.64 M(-35.8%) |
| June 2006 | - | -$3.36 M(-17.0%) | -$15.03 M(+3.0%) |
| Mar 2006 | - | -$4.05 M(-7.5%) | -$14.59 M(+11.4%) |
| Dec 2005 | -$13.37 M(+46.1%) | -$4.38 M(+35.4%) | -$13.10 M(+50.2%) |
| Sept 2005 | - | -$3.23 M(+10.5%) | -$8.72 M(+58.9%) |
| June 2005 | - | -$2.93 M(+14.2%) | -$5.49 M(+114.2%) |
| Mar 2005 | - | -$2.56 M | -$2.56 M |
| Dec 2004 | -$9.14 M(+121.8%) | - | - |
| Dec 2003 | -$4.12 M | - | - |
FAQ
- What is Mirati Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Mirati Therapeutics?
- What is Mirati Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Mirati Therapeutics?
- What is Mirati Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Mirati Therapeutics?
What is Mirati Therapeutics annual earnings before interest & taxes?
The current annual EBIT of MRTX is -$759.59 M
What is the all time high annual EBIT for Mirati Therapeutics?
Mirati Therapeutics all-time high annual earnings before interest & taxes is -$1.95 M
What is Mirati Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of MRTX is -$172.05 M
What is the all time high quarterly EBIT for Mirati Therapeutics?
Mirati Therapeutics all-time high quarterly earnings before interest & taxes is $9.29 M
What is Mirati Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of MRTX is -$764.87 M
What is the all time high TTM EBIT for Mirati Therapeutics?
Mirati Therapeutics all-time high TTM earnings before interest & taxes is -$2.49 M